Signals
ASCO 2026: AI is entering cancer care before the rules are ready
Artificial intelligence is no longer knocking on the door of oncology. It is already inside. At ASCO 2026, AI was not discussed as a distant promise or a shiny add-on to future cancer care. It was everywhere: clinical decision support, pathology, endoscopy, trial matching, patient information, biomarker discovery, workflow management and precision treatment selection. That…
MS Monitoring Starts Moving Beyond the MRI Bottleneck
Latin America Challenges the Dementia Biomarker Evidence Gap
China’s Alzheimer’s Blood-Test Rollout Turns Diagnosis Into an Access Market
Alzheimer’s Blood Testing Moves Toward Routine Care
Oncology Trials Still Do Not Match the Patients They Will Treat
Cancer Pharmacogenomics Exposes an Ancestry Gap in Routine Testing
Biomarker Testing Is Rising, But Eligibility Still Gets Lost
Colon Cancer MRD Testing Is Nearing the Access Threshold
Breast Cancer Blood Tests Could Bring Treatment Decisions Earlier
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.